Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Genflow in the mix. Gla ;-)
September 2023
Pfizer-backed VitaDAO spins out biotech company
VitaDAO, which funds longevity research, announced the $300,000 financing of a biotechnology company, the DAO's first such investment
hTtps://blockworks.co/news/vitadao-pfizer-biotech-arm
............
Vitadao
VDP-117 Magnaetus Therapeutics
Proposals
Active Proposals
.......................
Reviewer 2
Although no direct relationship or direct mechanistic action with aging, I am enthusiastic about their idea to use parts of the ECM and the protein of interest to target obesity (and metabolic dysregulation), which definitely will have a big impact on the aging society. Also, if they succeed, Novo Nordisk or Eli Lilly is likely to acquire them.
Reviewer 3
After reevaluating the data based on the company’s answers, they do indeed look promising and would allow VitaDAO to enter the weight-loss market. From a commercial perspective, my key concerns are the limited knowledge by the team of what is being developed outside of the two weight-loss drugs that are already commercialized and the lack of a Target Product Profile to be presented to physicians for feedback. I would also recommend as soon as it is feasible to generate head-to-head data vs semaglutide (Novo Nordisk) and tirzepatide (Eli Lilly). Also, given the size of the market, this is not a drug that can be developed and sold on its own, and Business Development activities targeted at Big Pharma must be initiated as soon as possible
hTtps://gov.vitadao.com/t/vdp-117-magnaetus-therapeutics/1417
hTtps://gov.vitadao.com/t/vdp-117-magnaetus-therapeutics/1417
Global online DAO approves launch and financing of MatrixBio to optimal drug candidates for age-related diseases.
VitaDAO, the global online community driving early-stage longevity research through innovative funding collaborations has announced the launch of its very first biotech company – Matrix Biosciences. This significant milestone comes from a community-wide vote and approval in favor of a collaboration with Vera Gorbunova, PhD, Co-Chair of the University of Rochester’s Aging Research Center.
htTps://longevity.technology/news/vitadao-community-launches-its-first-biotech-company/
Another potential imminent non-dilutive award for Genflow, who were awarded a $50k prize in September 2023 along with a new collaboration with Magnaetus Therapeutics from the healthspan challenge and now go forward to the next stage of the challenge, where $1 million will be awarded in January 2024 for the most promising longevity therapies, followed by a grand prize of $5m in June. Gla ;-)
September 2023
Developing therapeutic agents reverse ageing and metabolic decline
Cary Depel; Paul Baldock; Guy Barry |
Magnaetus Therapeutics; Eric Leire, MD | Genflow Biosciences
Competition Sponsor: US National Academy of Medicine
Awardee Year: 2023
Magnaetus Therapeutics believes that in order for longevity measures to be most effective, lifespan increases must be twinned with supportive metabolic interventions. This will ensure the ultimate aim of greater quality, as well as quantity of life, for the increasing majority of our population that is overweight/obese.
To deliver on this aim, Magnaetus is working with Genflow Biosciences to develop peptide therapeutics based upon the multiple metabolic activities of a novel circulating protein. Serum levels of this hormone are increased by exercise and calorie restriction, and suppressed by ageing, obesity and inactivity. It exhibits endocrine effects across numerous aspects of the energy economy, acting to mimic the downstream benefits of exercise and calorie restriction.
Longevity is directly targeted through a feed-forward loop with mTOR suppression. This is coupled with additional capabilities, including appetite suppression, fat burning and insulin production/sensitivity. The discrimination of these activities is realised through selection of individual loops of the parent protein’s repeated helical structure, enabling tailoring of therapeutic response to patient needs through production of specific peptide therapeutics.
htTps://healthylongevitychallenge.org/winners/developing-therapeutic-agents-reverse-ageing-and-metabolic-decline/
hTtps://healthylongevitychallenge.org/event/2023-healthy-longevity-global-innovator-summit/
Has to be the cheapest pharma listed relative to assets and cash.
How the obsession with longevity is shaping the future of skin care
Anti-ageing skin care is on the brink of change. Longevity scientists are raising the bar with an approach that makes skin biologically younger
Can we ‘cure’ ageing? The question came to the forefront in 2023, fuelled by a heady mix of compelling scientific developments and investment from multi-millionaire tech entrepreneurs, against a backdrop of an ageing global population and the recent pandemic.
Together, this has culminated in a borderline obsession with ‘longevity’.
Numerous scientific studies have supported a dramatic increase in longevity in the coming decades, extending the human lifespan to 120 or even beyond.
Breakthroughs such as the successful transfer of a ‘longevity gene’ from naked mole rats to mice, that improved the overall health and lifespan of the mice, are now the stuff of fact, not fiction.
And while ‘longevity’ may have been one of this year’s most popular buzzwords, it has also become a rapidly growing industry, one that is poised to have a profound impact on beauty and wellness in the future.
https://cosmeticsbusiness.com/how-the-obsession-with-longevity-science-is-shaping
So basically the new grants account for 50% of the current mcap and will give Genflow a decent cash runway towards commercialisation, without share dilution.
As more grants become available in longevity, where insurance companies and health agencies are realising it is better to tackle health conditions proactively rather than reactively, no doubt the team will look to further add funds.
No doubt companies will also be interested in using Genflows research for their own commercial line, as did Estee Lauder with the Bucks Institute, so the upside seems quite high atm.
Longevity biotech collaborates with Revatis and EXO Biologics on new research into sarcopenia and SIRT6 MRNA delivery.
Longevity biotech Genflow Biosciences has teamed up with Revatis and EXO Biologics on two new longevity research programs, fueled by grants from the Government of Wallonia in Belgium. Genflow is developing gene therapies that target the aging process, with a focus on reducing and delaying age-related diseases.
One of the new research programs, conducted in collaboration with cell therapy company Revatis, is focused on addressing the issue of age-related muscle loss. With funding of €1.34 million, the three-year initiative aims to provide insights into the mechanisms of sarcopenia – the muscle deterioration associated with aging.
Simultaneously, Genflow and exosome-focused biotech EXO Biologics are embarking on a three-year scientific program focusing on mRNA delivery. Supported by a grant of €1.55 million, the initiative will explore an approach using exosomes to encapsulate and transport Genflow’s SIRT6 gene therapy. The ultimate goal is to enable the development of therapeutic interventions for Werner Syndrome, an accelerated aging condition, and other age-related conditions.
Dr Eric Leire, CEO of Genflow said that the new research programs will allow the company to make “meaningful advancements” in the field of longevity.
“Launching both of these programs represents a strategic move to enhance our research capabilities, while contributing to the understanding of age-related conditions,” he said.
Genflow is currently developing a pipeline of SIRT6 gene therapies, with three programs targeting Werner Syndrome, an aggressive form of non-alcoholic fatty liver disease (NASH), and pet longevity. The company’s lead compound is a suspension of an adeno-associated viral vector-based gene therapy based on a variant of the human SIRT6 gene, which is associated with longevity in centenarians.
Disclosure: First Longevity Ltd which operates this website (Longevity.Technology) has a commercial interest in Genflow Biosciences Ltd.
hTtps://longevity.technology/news/genflow-launches-two-grant-funded-longevity-research-programs/
Agree with Dave. How many pharma companies do you see being awarded government grants, and to such a large sum? If it had been NHS grants, the UK investors would have been a bit more appreciative of the work Genflow are achieving.
Basically, the Wallonia counsellors have to go to the European Union and ask for permission to issue such grants, as they come from taxpayers funds. That means, Genflow is a EU parliamentary endorsed company. When you have global leaders behind you backing your research, the buy out cheque book starts to dance and long term investors will benefit greatly from their patience…imo
You do know that Eric has mentioned that there will be a trading update this month.
Look at the comments on Linked in under GenFlow
So expect more rises to come as Eric has known to deliver good news.
Well said Dave,
It's the same names that pop up on every board.
Do you own research on the people that are posting it won't take you long to work out what they are doing
Any sensible investor will wait to invest once the numpties who post on risers everyday bugger off.
Hopefully it won't be long to see them leave.
Remember this share is 100 % for a buyout for any LTI.
I know a few, including me who are going long term on this.
There is no rewards for the typical 5-10 % pumper who makes their £45 and move on.
Market Cap of just under 6 million with grants up to 10 million.
All good and much more to come, including..... well, if you know, you know :)
Thanks
Hi Gordonbennett
look at BIDS
bidstack
thanks
Probably a few fresh pairs of eyes here due to the recent rise.
I am a relatively long term holder considering the short lived nature of GENF. It's my largest 'speculative' holding.
Be wary of the hype. There's been a slew of good news that had pushed the price up, even to test 5p, but it has yet to sustain. I believed we would see 10p 2023 but that was not the case, regardless of the great progress within the company.
Read the fundamentals, ignore the comments (this one too!), don't get caught up holding onto shares you can't afford to hold onto if we do see a retreat.
I am very happy with the progress. I love non diluting funding. I think this company has a great future. I will continue to buy and hold.
I don't like people getting caught up in the excitement and ending up 60%+ in a loss because they bought in on a hype swing.
Good luck everyone! :)
Aim?
Mm looks keen to get things moving this am.
Great posts gents! Let’s see a move north back ipo would be nice!! Eric bringing these non dilutive packages are genius and something very unique on aim
Sam Altman (Open AI) - Invested $180m in longevity start up
https://www.technologyreview.com/2023/03/08/1069523/sam-altman-investment-180-million-retro-biosciences-longevity-death/amp/
Bryan Johnson (Sold last company to PayPal for $800m) Now uses that money to fund his own longevity research
https://fortune.com/2023/07/14/bryan-johnson-spending-2-million-young-forever/amp/
Q. What’s the only thing money can’t buy?
A. Time
Q. What if that’s wrong and you can?
Revatis SA
Innovation in cellular therapy
Revatis is a Spin Off from the University of Liège, dedicated to regenerative medicine and cell therapy. Revatis is based on the scientific discoveries of Prof. D. Serteyn and Dr J. Ceusters and has solid intellectual property and exceptional know-how.
Revatis has a patented technology for obtaining multipotent stem cells from a muscle micro-biopsy. This technology is available for clinical applications in veterinary medicine and for research in human medicine.
In veterinary medicine, Revatis aims to produce autologous stem cells for therapeutic use in horses and companion animals. In human medicine, Revatis is positioning itself as a supplier of personalized stem cells for banking, research, organ-on-a-chip and 3D bioprinting.
htTps://revatis.com/en
.....
Exo Biologics
Unlocking the Potential of Exosomes: The Next Frontier of Nanomedicine
Exosomes are nanometer-sized vesicles containing bioactive molecules secreted by cells. They can be used for the targeted delivery of therapeutic agents.
Exosomes are specific extracellular vesicles that carry RNA, Lipids, and protein messengers, naturally released by various cells. They induce and modulate distinct effects on targeted cells. Depending on their cellular origin, exosomes can also be loaded with specific bioactive molecules, and they have a potency and targeting ability.
EXOB-001, Our Lead Product Candidate
EXOB-001 Investigational Medical Product (IMP) consists of a sterile suspension of allogeneic extracellular vesicles (EVs) derived from cultured human umbilical cord mesenchymal stromal cells (hMSCs).
Human MSCs are characterized by their ability to, among other things, secrete various growth factors and cytokines that modulate the immune system and promote tissue repair and regeneration.
hTtps://www.exobio.be/en/
GenFlow Biosciences
1,413 followers
7h
GenFlow Biosciences (LSE: GENF) (OTCQB: GENFF) is thrilled to announce its partnership with Revatis SA and EXO Biologics in Groundbreaking Aging Research, Fueled by Two Major Research Grants 🧬
"The two research programs are a part of a broader innovation partnership that the Walloon Government has launched, dedicated to Advanced Therapy Medicinal Products (ATMPs). The partnership boasts a substantial budget of 81 million euros, a mix of 60% public funding and 40% private contributions from various companies, spread over three years. This initiative is a collaborative effort involving BioWin, the Health Cluster of Wallonia and the Public Service of Wallonia, representing a significant commitment to advancing medical research and development in the region."
Read more about the exciting new venture here: hTtps://loom.ly/dF-wrxc
#ageing #longevity #healthspan #smallcap
LONDON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Genflow Biosciences Plc (Genflow or the "Company”) (LSE:GNF) (OTCQB:GENFF), an emerging leader in the field of longevity research developing therapeutics that potentially halt or slow the ageing process, in collaboration with Revatis SA and EXO Biologics, is proud to announce the initiation of two significant research programs backed by substantial non-diluting and non-reimbursable research grants by the Government of Wallonia in Belgium. Both of these strategic initiatives will strengthen Genflow’s position at the forefront ageing-related research, and its mission to improve the health and well-being of older adults.
And this one? :-)
9.3218849
VARIANTS OF SIRT6 FOR USE IN PREVENTING AND/OR TREATING AGE-RELATED DISEASES
CA - 17.11.2022
Int.Class
C12N 15/113
Appl.No 3218849
Applicant UNIVERSITY OF ROCHESTER
Inventor GORBUNOVA, VERA
The present invention relates to an isolated nucleic acid molecule encoding a variant of sirtuin 6 (SIRT6) having at least 75% identity with sequence SEQ ID NO: 1, the variant having at least one mutation selected in the group comprising or consisting of a N308K substitution and a A313S substitution with respect to sequence SEQ ID NO: 1. The invention provides means for the regulation of ageing, and/or senescence, and/or lifespan in an individual. The invention further provides means for the repair of double strand breaks in a cell. Finally, the invention also provides means for the prevention and/or the treatment of an age-related disease.
Don’t forget Vera’s patent too: US 63/188,573 14.05.2021
12 months since a crucial patent application, not just for Genflow but a breakthrough for gene therapy and longevity research according to Eric, which could add massive value if awarded. It can take up to 2 years for approval, but the US Patent Office can award within 12 months if accelerated, and so news at anytime which would be truly transformational for all concerned. Gla :-)
"Genflow has expanded its intellectual property portfolio with a provisional patent application focusing on the SIRT6 gene editing. If granted, this patent could mark a significant breakthrough in gene therapy and longevity research."
1.20230018934
METHOD OF IN VIVO ADMINISTRATION OF THE CODING SEQUENCE OF THE SIRT6 GENE VIA ADENO-ASSOCIATED VIRUS
US - 19.01.2023
Int.Class
A61K 48/00
Appl.No 17865688
Applicant GENFLOW BIOSCIENCES SRL
Inventor Eric LEIRE
Methods for in vivo administration of the coding sequence of the sirt6 gene. In particular, methods that include the administration of adeno-associated virus vectors or recombinant adeno-associated virus vectors including the coding sequence of the sirt6 gene.
3p plus next stop with more of the same tomorrow with any luck. Gla holders...more good news at anytime. :-)
Great to see a buzz again after a long period of no news! Eric is a genius
Closing on days high! Tomorrow looks fruitful